Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.

The Journal of pediatrics - 1 May 2009

Patiño-García Ana, Zalacaín Marta, Marrodán Lucía, San-Julián Mikel, Sierrasesúmaga Luis

Abstract excerpt

OBJECTIVE: To determine the influence of the genotype and the level of expression of different enzymes involved in folate metabolism on the response to and toxicity of high-dose methotrexate treatment in pediatric osteosarcomas. STUDY DESIGN: DHFR and Reduced folate carrier 1 (RFC1) semiquantitative expression was analyzed in 34 primary and metastatic osteosarcoma tissues by real-time polymerase chain reaction....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastrointestinal Diseases

Share to Hematologic Diseases

Share to Kidney Diseases

Share to Methotrexate

Share to Osteosarcoma

Share to Tetrahydrofolate Dehydrogenase

Source

Identifiers

PMID: 19159907
DOI: 10.1016/j.jpeds.2008.11.030

Genes

RFC1
DHFR
MTHFR
MTR
TYMS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.PMID 19159907Read ↗

The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients.Semantic proximity Read ↗

Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcomaSemantic proximity Read ↗

ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma.Semantic proximity Read ↗

Impact of Pharmacogenetics on High-Dose Methotrexate Toxicity in Pediatric OncologySemantic proximity Read ↗

Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate.Semantic proximity Read ↗

ABCC2(rs717620), and ABCC3 (rs4793665) affect high dose Methotrexate toxicity, and outcome in children with osteosarcomaSemantic proximity Read ↗

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.Semantic proximity Read ↗

Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcomaSemantic proximity Read ↗

Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.Semantic proximity Read ↗

Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients.Semantic proximity Read ↗

Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis.Semantic proximity Read ↗

MTHFR variants 677TT and 677CT/1298AC are associated with decreased tolerance to methotrexate in pediatric acute lymphoblastic leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.